Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsTest your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!
Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.
A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
AI catches one-third of interval breast cancers missed at screening
2.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
3.
Scientists call into question safety of potential new anticancer treatment
4.
Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds
5.
Is Exercise an Effective Treatment for Prostate Cancer?
1.
How to Prevent Tumor Lysis Syndrome in Cancer Patients
2.
Genetic Screening: A Game Changer in Cancer Prevention
3.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
4.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
5.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge